Linezolid (LZD) has been reported
to cause severe hyponatremia, but infection per
se is also a potential cause of hyponatremia by increasing vasopressin
secretion. The author compared the incidence and risk of developing
hyponatremia between LZD and vancomycin (VCM) using propensity score analysis
to demonstrate that hyponatremia is associated with LZD rather than infection.
The analysis indicated a significantly higher incidence and 3.7-fold higher
risk of developing hyponatremia associated with LZD than with VCM, regardless
of patient background characteristics. Regularly monitoring serum sodium and
infusing sodium promptly when the level decreases would be required when
administering LZD.
Despite the fact that liver fibrosis is an
intractable disease with a poor prognosis, effective therapeutic agents are not
available. The authors
focused on bone morphogenetic factor 7 (BMP7) that
inhibits TGF-β signaling. They prepared a long-acting albumin-fused
BMP7 (HSA-BMP7) and evaluated its inhibitory effect on liver fibrosis. In the mice with bile duct ligation, HSA-BMP7 administration suppressed
the infiltration of inflammatory cells and fibrosis area around the bile duct. In the
carbon tetrachloride-induced liver fibrosis mice, HSA-BMP7 administration also decreased
the hepatic fibrosis. HSA-BMP7 has the potential for serving as a
therapeutic agent for the treatment of liver fibrosis.
The yeast strain Saccharomyces cerevisiae is an eukaryotic organism that secrete
extracellular vesicles (EVs). The authors
characterized the biodistribution of locally (intradermally and subcutaneously)
administered Saccharomyces
cerevisiae-derived EVs (S-EVs) and the EV-mediated immune responses to
evaluate their potential use as biocompatible vaccine adjuvants. Locally administered
S-EVs were delivered to the lymph nodes, mainly reaching the B-cell zone. Furthermore,
S-EVs increased the expression of cytokine and costimulatory molecules. Especially,
subcutaneously injected S-EVs showed potent adjuvanticity, indicating that
subcutaneous administration of S-EVs is the desirable approach for achieving
effective immune stimulation. These findings will facilitate the development of
novel EV-based immunotherapies.
Osteoporosis is caused by an imbalance between osteoblast
bone formation and osteoclast bone resorption, thus is treated with oral and
parenteral bone-resorption inhibitors and parenteral bone-formation promoting
drugs. The authors demonstrated that KY-054, a novel coumarin derivative, has osteoblast
differentiation-promoting activities in mouse and rat mesenchymal stem cells, increasing
metaphyseal and diaphyseal cortical bone volume and bone strength parameters without
reducing medullary volume by micro-computed tomography in ovariectomized rats. KY-054
is a potential orally active osteogenic anti-osteoporosis drug candidate with a
unique mode of action by acceleration of osteoblast differentiation.
Authors fabricated 3D-printed contact
lenses composed of polyethylene glycol diacrylate and an antibiotic,
azithromycin. The drug-loaded contact lenses were prepared using vat
photopolymerization 3D printer, and the effect of second curing on 3D printed
object was investigated. The mechanical strength and drug release of contact
lens formulation were evaluated in the present study. The 3D printed contact
lenses exhibited antimicrobial effect in vitro. The current results suggested
that the preparation of antibiotic-loaded contact lenses by 3D printing
provides useful information for manufacture of ophthalmic device and
personalized therapy.